Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 12;32(2):99–103. doi: 10.1002/clc.20297

Safety of Intra‐aortic Balloon Pump Using Glycoprotein IIb/IIIa Antagonists

Avishag Laish‐Farkash 1,2,✉, Hanoch Hod 1,2, Shlomo Matetzky 1,2, Victor Guetta 1,2
PMCID: PMC6653343  PMID: 19215010

Abstract

Background

Anticoagulation with heparin is recommended with intra‐aortic balloon pump (IABP) to prevent thrombosis and embolization. However, anticoagulation increases the risk of bleeding, particularly in combination with glycoprotein (GP) IIb/IIIa antagonists.

Hypothesis

We investigated the safety of using GP IIb/IIIa antagonists without heparin after IABP insertion in patients who underwent primary percutaneous coronary intervention (PCI).

Methods

Consecutive patients with acute myocardial infarction (AMI), who underwent primary PCI and were treated with GP IIb/IIIa antagonists without concomitant heparin, and in whom IABP was inserted, were followed during hospitalization for thrombotic and hemorrhagic complications.

Results

Ninety‐seven patients were included in this analysis. Glycoprotein IIb/IIIa antagonist treatment duration was 12–24 h in 89% of patients, and IABP duration was up to 48 h in 97% of patients. Three patients (3.1%) developed vascular complications: 1 had a major limb ischemia (long IABP treatment), 1 had a minor limb ischemia, and 1 had a cerebrovascular event (after prolonged resuscitation). All patients were already on heparin at the time of the thrombotic events. The rates of major and minor bleeding complications were 9% and 15.5%, respectively.

Conclusions

The rate of thrombotic complications is relatively low in post‐primary PCI patients with IABP treated with GP IIb/IIIa antagonists without concomitant heparin therapy. Such an approach may reduce the risk of hemorrhagic complications, with low risk of thrombotic complications. Copyright © 2009 Wiley Periodicals, Inc.

Keywords: intra‐aortic balloon pump, myocardial infarction, glycoprotein IIb/IIIa antagonists, complications

Full Text

The Full Text of this article is available as a PDF (103.1 KB).

References

  • 1. Sutorius DJ, Majeski JA, Miller SF: Vascular complications as a result of intra‐aortic balloon pumping. Am Surg 1979; 45: 512–516. [PubMed] [Google Scholar]
  • 2. Trost JC, Hillis LD: Intra‐aortic balloon counterpulsation. Am J Cardiol 2006; 07: 1391–1398. [DOI] [PubMed] [Google Scholar]
  • 3. Jiang CY, Zhao LL, Wang JA, Mohammod B: Anticoagulation therapy in intra‐aortic balloon counterpulsation: Does IABP really need anti‐coagulation? J Zhejiang Univ Sci 2003; 4: 607–611. [DOI] [PubMed] [Google Scholar]
  • 4. Kuki S, Taniguchi K, Masai T, Yoshida K, Yamamoto K, et al.: Usefulness of the low profile “True 8” intra‐aortic balloon pumping preventing limb ischemia. ASAIO J 2001; 47(6): 611–614. [DOI] [PubMed] [Google Scholar]
  • 5. Ferguson JJ, Cohen M, Freedman RJ, Stone GW, Miller MF, et al.: The current practice of intra‐aortic balloon counterpulsation: Results from the Benchmark Registry. J Am Coll Cardiol 2001; 38: 1456–1462. [DOI] [PubMed] [Google Scholar]
  • 6. Cohen M, Urban P, Christenson JT, Joseph DL, Freedman RJ Jr, et al.: Benchmark Registry Collaborators: Intra‐aortic balloon counterpulsation in US and non‐US centers: results of the Becnchmark Registry. Eur Heart J 2003; 24: 1763–1770. [DOI] [PubMed] [Google Scholar]
  • 7. Meco M, Gramegna G, Yassini A, Bellisario A, Mazzaro E, et al.: Mortality and morbidity from intra‐aortic balloon pumps. Risk analysis. J Cardiovasc Surg 2002; 43: 17–23. [PubMed] [Google Scholar]
  • 8. Cohen M, Dawson MS, Kopistansky C, McBride R: Sex and other predictors of Intra‐aortic balloon pump complication: prospective study of 1119 consecutive patients. Am Heart J 2000; 139: 282–287. [DOI] [PubMed] [Google Scholar]
  • 9. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, et al.; The EPIC Investigators : Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrelin in patients undergoing percutaneous coronary intervention. EPIC investigators. Circulation 1995; 91: 2882–2890. [DOI] [PubMed] [Google Scholar]
  • 10. Dogrell SA: Clinical trials with glycoprotein IIb/IIIa antagonists–no benefit without bleeding? Drugs Today (Barc) 2001; 37: 509–531. [DOI] [PubMed] [Google Scholar]
  • 11. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, et al.: Randomized, placebo‐controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734–741. [DOI] [PubMed] [Google Scholar]
  • 12. Galeote G, Hussein M, Sobrino N, Calvo L, Sanchez‐Recalde A, et al.: Use of a combination of enoxaparin or unfractionated heparin and abciximab during percutaneous coronary interventions: a randomized pilot study. Rev Esp Cardiol 2002; 55: 1261–1266 (Spanish). [DOI] [PubMed] [Google Scholar]
  • 13. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, et al.: Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930–935. [DOI] [PubMed] [Google Scholar]
  • 14. Lacy CF, Armstrong LL, Goldman MP, Lance MP: Drug Information Handbook International (12th edition). Ohio: Lexi‐Comp Inc, 2004–5. [Google Scholar]
  • 15. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, et al.: Hemorrhagic events during therapy with recombinant tissue‐type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991; 115: 256–265. [DOI] [PubMed] [Google Scholar]
  • 16. Stone GW, Ohman EM, Miller MF, Joseph DL, Christenson JT, et al.: Contemporary utilization and outcomes of intra‐aortic balloon counterpulsation in acute myocardial infarction: the Benchmark Registry. J Am Coll Cardiol 2003; 41: 1940–1945. [DOI] [PubMed] [Google Scholar]
  • 17. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, et al.: ACC/AHA guidelines for the management of patients with ST‐elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on practice Guidelines. J Am Coll Cardiol 2004; 44: 671–719. [DOI] [PubMed] [Google Scholar]
  • 18. TitcolorMahaffey KW, TitcolorGranger CB, TitcolorSloan MA, TitcolorThompson TD, TitcolorGore JM, et al.; GUSTO‐1 Investigators : Risk factors for in‐hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis. Circulation 1998; 97: 757–764. [DOI] [PubMed] [Google Scholar]
  • 19. Angeja BG, Rundle AC, Gurwitz JH, Gore JM, Barron HV: Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator: participants in the National Registry of Myocardial Infarction 2. Am J Cardiol 2001; 87: 627–630. [DOI] [PubMed] [Google Scholar]
  • 20. Spencer FA, Gore JM, Yarzebski J, Lessard D, Jackson EA, et al.: Trends (1986 to 1999) in the incidence and outcomes of in‐hospital Titcolorstroke complicating acute myocardial infarction (the Worcester heart attack study). Am J Cardiol 2003; 92: 383–388. [DOI] [PubMed] [Google Scholar]
  • 21. Budaj A, Flasinska K, Gore JM, Anderson FA Jr, Dabbous OH, et al.; GRACE Investigators : Magnitude of and risk factors for in‐hospital and postdischarge stroke in patients with acute coronary syndromes. Findings from a global registry of acute coronary events. Circulation 2005; 111: 3242–3247. [DOI] [PubMed] [Google Scholar]
  • 22. Azeem T, Stephens‐Lloyd A, Spyt T, Hartshorne R, Gershlick AH: Intra‐aortic balloon counterpulsation: variations in use and complications. Int J Cardiol 2004; 94: 255–259. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES